- Home
- AES vs LEGN Comparison
AES vs LEGN Comparison
Compare AES & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AES | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 5.9B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AES | LEGN |
|---|---|---|
| Price | $14.81 | $20.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $15.29 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 6.2M | 1.8M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $12,233,000,000.00 | N/A |
| Revenue This Year | $5.22 | $42.68 |
| Revenue Next Year | $4.81 | $30.52 |
| P/E Ratio | $11.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.33 | $16.24 |
| 52 Week High | $17.65 | $37.50 |
Technical Indicators
Market Signals| Indicator | AES | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 45.09 |
| Support Level | $14.64 | $19.96 |
| Resistance Level | $14.88 | $21.97 |
| Average True Range (ATR) | 0.05 | 0.99 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 80.00 | 25.86 |
Price Performance
Historical ComparisonAbout AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy, gas, coal, and oil. AES has majority ownership in and operates numerous electric utilities.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.